Thoratec (THOR) was upgraded by UBS (UBS) from neutral to buy with a price target of $39, as the share price is inexpensive given the position the company has in a growth market.
Shares are higher by about 3.5 percent.
Medivation (MDVN) had its numbers increased Citigroup (C) to reflect the higher US price of Xtandi. A buy rating was issued with a price target of $70.
Shares are lower by almost two tenths of a percent.